Significant Linkage of Parkinson Disease to Chromosome 2q36-37  by Pankratz, Nathan et al.
Am. J. Hum. Genet. 72:1053–1057, 2003
1053
Report
Significant Linkage of Parkinson Disease to Chromosome 2q36-37
Nathan Pankratz,1 William C. Nichols,2 Sean K. Uniacke,2 Cheryl Halter,1 Alice Rudolph,3
Cliff Shults,4,5 P. Michael Conneally,1 Tatiana Foroud,1 and the Parkinson Study Group*
1Department of Medical and Molecular Genetics, Indiana University Medical Center, Indianapolis; 2Division of Human Genetics, Cincinnati
Children’s Hospital Medical Center, Cincinnati; 3Department of Neurology, University of Rochester, Rochester, NY; and 4Department
of Neurosciences, University of California, San Diego, and 5VA San Diego Healthcare System, San Diego
Parkinson disease (PD) is the second most common neurodegenerative disorder, surpassed in frequency only by
Alzheimer disease. Elsewhere we have reported linkage to chromosome 2q in a sample of sibling pairs with PD.
We have now expanded our sample to include 150 families meeting our strictest diagnostic definition of verified
PD. To further delineate the chromosome 2q linkage, we have performed analyses using only those pedigrees with
the strongest family history of PD. Linkage analyses in this subset of 65 pedigrees generated a LOD score of 5.1,
which was obtained using an autosomal dominant model of disease transmission. This result strongly suggests that
variation in a gene on chromosome 2q36-37 contributes to PD susceptibility.
Parkinson disease (PD [MIM 168600]) is a common
neurodegenerative disorder, affecting 3% of those 175
years of age (de Rijk et al. 1997). It is associated with
resting tremor, postural rigidity, and progressive accu-
mulation of protein inclusions containing ubiquitin and
a-synuclein in the substantia nigra. The first causative
PD mutation was identified in the a-synuclein gene on
chromosome 4; however, only two mutations in a very
small number of families have thus far been reported
(Gwinn-Hardy 2002). Subsequently, mutations in the
parkin gene on chromosome 6 were reported to result
in autosomal recessive, juvenile parkinsonism (ARJP
[MIM 600116]). Mutations in this gene may account
for PD in as many as 50% of familial cases of ARJP
(Lu¨cking et al. 2000) and may also result in individuals
with idiopathic late-onset PD, particularly those with a
positive family history (Foroud et al. 2003). Recently,
mutations in the DJ-1 gene on chromosome 1q were
found to result in autosomal recessive, early-onset PD
(Bonifati et al. 2002). In addition, linkage to four other
chromosomal regions has been reported in families seg-
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regating either an autosomal dominant or an autosomal
recessive form of PD; however, the causative genes have
not yet been identified (Gwinn-Hardy 2002). We have
recently identified linkage to chromosome 2q36–37 in
a sample of 170 affected sibling pairs (Pankratz et al.
2002).
To identify susceptibility genes for PD, affected sibling
pairs and more extended multiplex families with PD
were recruited through the movement-disorder special-
ists of the Parkinson Study Group (PSG), a network of
60 centers located throughout North America. During
an in-person study visit, the Diagnostic Checklist (Nich-
ols et al. 2002; Pankratz et al. 2002) was completed by
the neurologist; inclusion criteria consisted of clinical
features highly associated with autopsy-confirmed PD,
and exclusion criteria consisted of features highly as-
sociated with other non-PD pathological diagnoses
(Hughes et al. 1992a, 1992b). Responses on the Diag-
nostic Checklist were used to classify study participants
as having verified PD (417 subjects) or nonverified PD
(163 subjects). Peripheral blood was obtained from all
individuals after they completed the appropriate written
informed consent form approved by each center’s insti-
tutional review board.
A marker in intron 7 of the parkin gene (D6S305)
was genotyped to identify families more likely to have
a mutation in this known PD-susceptibility gene. Fam-
ilies having a positive LOD score at this marker (as de-
termined using an autosomal recessive model of disease
1054 Am. J. Hum. Genet. 72:1053–1057, 2003
Table 1
Demographic Information and LOD Scores for Families with Verified PD
SAMPLE
NO. OF
%
MALE
MEAN  SD
AGE AT
ONSET
(years)
LOD SCORE
Families
Sibling
Pairs
Including Families
with parkin Mutations
Excluding Families
with parkin Mutations
Original 104 116 61 60.4  11.8 3.05a 1.87a
Expanded 150 170 60 60.0  12.1 3.51a 2.47a
Strong family history 65 77 57 58.0  12.2 5.14b 4.12b
a Nonparametric LOD scores computed with Mapmaker/Sibs.
b Parametric LOD scores computed using an autosomal dominant model with 80% penetrance, 0.005 disease allele
frequency, and a 3% phenocopy rate.
inheritance [ ]), along with families that includednp 94
at least one affected individual with an age at onset50
years ( ; overlap ), were screened fornp 66 np 30
parkinmutations, using both direct sequencing and fluo-
rescent-dosage PCR analysis (Nichols et al. 2002). Link-
age analyses on chromosome 2 were performedwith and
without the 47 families determined to have parkin
mutations.
Thirty dinucleotide repeat markers from the ABI
Prism Linkage Mapping Set (Applied Biosystems), with
an average heterozygosity of 80% and an average in-
termarker spacing of 8.7 cM, were genotyped on chro-
mosome 2. Marker order and the genetic distances be-
tween markers were estimated from the sex-averaged
genetic maps from Marshfield Genetic Laboratory, ABI
(ABI Linkage Mapping Set 2), and deCode (Kong et al.
2002). The maximum LOD score was within 0.01 for
all analyses using the different maps. Therefore, only
results obtained using the maps generated from Marsh-
field are reported. PCR amplification was performed for
each of the markers, and the products were separated
by electrophoresis, using an ABI 3700 DNA Analyzer
(Applied Biosystems). Genotypes were determined by
Genescan 3.5, Genotyper 3.6, and Genemapper 2.0 soft-
ware. Mendelian errors in the genotypic data were de-
tected using the program PedCheck (O’Connell and
Weeks 1998), and the marker genotypic data were
used to verify all reported family relationships among
the subjects, using the computer program Relative (Gor-
ing and Ott 1997). Allele frequencies were estimated
from the full PD cohort of 1,352 chromosomes, using
the Userm13 module from the Mendel software package
(Lange et al. 1988). Nonparametric multipoint LOD
scores were calculated using Mapmaker/Sibs (Kruglyak
and Lander 1995).
We previously reported evidence of linkage to chro-
mosome 2q (LOD p 3.1) in a sample of 104 families
in which the affected individuals met the strictest di-
agnosis of PD (i.e., verified PD) (table 1; Pankratz et al.
2002). This sample included 90 families without a par-
kin mutation and 14 families with mutations in one or
both parkin alleles. We have subsequently ascertained
an additional 96 individuals from 46 families that meet
our strictest diagnostic criteria. These families provide
additional evidence of linkage to chromosome 2q36-37.
Combined analyses of the 150 families yielded suggestive
evidence of linkage in the region of three adjacent mark-
ers (D2S396, D2S206, and D2S338) and a resulting
maximum LOD score of 3.5 (table 1). A total of 25
families with parkin mutations were identified in the
initial and subsequently ascertained samples, including
14 families with a mutation in only one of their two
parkin alleles, three families with homozygous parkin
mutations, and eight families whose members were com-
pound heterozygotes. When the 25 families with mu-
tations in the parkin gene were removed from the sam-
ple, the LOD score was reduced to 2.5. The increased
LOD score that resulted from the inclusion of the fam-
ilies that were positive for the parkinmutation may sug-
gest a potential epistatic or additive interaction between
the parkin gene and a chromosome 2q susceptibility lo-
cus. Most reported parkin mutations have been found
only in patients with PD, but at least one of the muta-
tions observed in our cohort (Ser167Asn) has been ob-
served in a few control individuals who did not have
PD (Oliveri et al. 2001). Therefore, it is possible that a
mutation in only one of the two parkin alleles is not
sufficient to cause PD. Rather, a mutation in a second
PD susceptibility locus may be required for manifesta-
tion of disease.
Subsequent analyses were designed to further eluci-
date the role of the chromosome 2q susceptibility locus.
A subset of families was identified that met the strictest
diagnostic criteria of verified PD and also had a stronger
family history of PD. We defined this subset as those
families having at least four first-, second-, or third-
degree relatives reported to have PD but not necessarily
examined ( families) and those families that in-np 40
cluded an affected sibling pair who also had a parent
reportedly diagnosed with PD ( ). The overlapnp 49
between these two groups was substantial ( ). Anp 24
total of 65 families with verified PD were thus identified
who were considered to have a more extensive family
history. On the basis of the results of the previous anal-
yses suggesting a potential interaction between parkin
and the locus on 2q, kindreds meeting these family his-
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Figure 1 Autosomal dominant multipoint LOD score plot for the 65 families with a strong family history of PD
tory criteria were included in the analysis regardless of
the presence or absence of a parkin mutation(s).
It has been shown that employing a single-gene model
for a disease with potentially complex inheritance can
result in a potential gain in power, even if the disease
model is incorrectly specified (Abreu et al. 1999; Hodge
et al. 2002). Therefore, after review of our families with
a strong family history of PD, an autosomal dominant
model of PD susceptibility was postulated with 80%
penetrance, a disease allele frequency of 0.005, and a
3% phenocopy rate. Two-point LOD scores were cal-
culated using the MLINK program of the LINKAGE
software package (Lathrop and Lalouel 1984). This
model yielded a maximum two-point LOD score of 3.0
for at marker D2S206. As with the nonparametricvp 0
analyses, the flanking markers D2S396 ( )LODp 2.9
and D2S338 ( ) also provided evidence ofLODp 2.4
linkage under this model. The program Allegro (Gud-
bjartsson et al. 2000) was then used to perform multi-
point linkage analysis, using this same parametric dis-
ease model. A maximum multipoint LOD score of 5.1
was computed at the marker D2S206 (fig. 1). Variation
in marker allele frequencies resulted in only minor
changes in the maximum LOD score. The 11 families
positive for parkin mutation contributed a summed
LOD score of 1.0. Given this relatively small sample of
parkin-positive families with verified PD, it will be im-
portant to further study parkin-positive families to test
whether there is evidence for an epistatic or additive
interaction between the parkin locus and a PD suscep-
tibility gene on chromosome 2q.
Elsewhere, linkage to an autosomal dominant PD lo-
cus on chromosome 2p (PARK3 [MIM 602404]) was
identified in a sample of families of European origin
(Gasser et al. 1998). More recently, analyses of affected
sibling pairs provided evidence that the PARK3 locus
might affect age at onset in late-onset PD (DeStefano et
al. 2002). However, our linkage to 2q36-37 is ∼140 cM
away and therefore represents linkage to a gene that is
distinct from the PARK3 locus.
In summary, our data provide strong evidence that a
susceptibility gene for PD is located within a 20-cM
region near the q terminus of chromosome 2. Future
studies will focus on identifying genes in this chromo-
somal region, which might be tested as candidates for
their role in PD susceptibility.
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